Ann: $29.6m Equity Placement to Lepu Medical Group of China, page-63

The facts need updating... the shares pre the cash injection were 240mm, so more like 276mm now excluding options. I would like to see the cost of the pivotal study before any comments on the current cash balance. .. two years ago 45mm was the same comment I believe.

I haven't finalised my view on Lepu.... cash is great but there are lots of ways that could of happened... Big pharma part funding the trials (i.e. Not just supplying their drugs). Maybe this will spark movement from them so I remain optimistic but confused.